BioCryst launches Orladeyo (berotralstat) in Italy
BioCryst Pharmaceuticals Inc today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended Orladeyo (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older.
With this recommendation, HAE patients in Italy now have access to the first oral, once-daily therapy for the routine prevention of recurrent HAE attacks.
Charlie Gayer, Chief Commercial Officer of BioCryst, said: “The positive AIFA recommendation of Orladeyo broadens access to modern prophylaxis in Italy and is great news for Italian clinicians and HAE patients.”
The AIFA decision follows European Commission (EC) marketing authorization of Orladeyo in April 2021.
(Source: BioCryst)
